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license (http://creativeheimer’s disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy.
Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark
can be detected antemortem. Practitioners and patients need to better understand potential diagnostic
benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications
surrounding this new technology. To complement the practical considerations, Eli Lilly and Company
sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of
amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best
address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this
technology be used only by experienced imaging and treating physicians in appropriately selected
patients and only in the context of a comprehensive clinical evaluation with adequate explanations
before and after the scan.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Amyloid-b positron emission tomography (hereafter
termed amyloid-PET) neuroimaging has been a useful tool
in Alzheimer’s disease (AD) research [1–3] and as a16/j.dadm.2015.06.006
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).technique for subject enrichment in AD clinical trials to
ensure that only those with underlying b-amyloid plaque
pathology are enrolled [4]. The recent clinical availability
of amyloid-PET now allows physicians to estimate theimer’s Association. This is an open access article under the CC BY-NC-ND
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mortem, and to assess whether significant amyloid-b burden
(moderate-to-frequent neuritic plaques needed to meet path-
ologic criteria for intermediate or high likelihood that AD
pathology is the cause of dementia) is present. However,
although amyloid-PET accurately detects the presence of
b-amyloid plaques, the scan by itself captures only one
core element of AD pathology (neuritic plaques but not
neurofibrillary tangles). For example, patients with amy-
loid-b pathology often have other neuropathologies such
as Lewy bodies or cerebrovascular disease, and interpreta-
tion may be further complicated by factors such as depres-
sion and cognitive impairment due to medications. As
amyloid-PET enters into clinical use, it is important that
practitioners and patients understand the potential diagnostic
benefits and limitations of amyloid-PET. Furthermore, they
need to recognize the complex practical, ethical, and social
implications surrounding this new technology.
To complement the practical considerations, Eli Lilly and
Company (Lilly) sponsored a multidisciplinary Bioethics
Advisory Board to consider bioethical issues that might arise
when using amyloid-PET as an adjunctive diagnostic tool to
clinically evaluate patients with cognitive impairment. Our
intent was not to propose evidence-based guidelines for clin-
ical use of amyloid-PET because these were already being
developed and subsequently published by the joint efforts
of the Society of Nuclear Medicine and Molecular Imaging
(SNMMI) and the Alzheimer’s Association (AA) [5,6].
Instead, we considered whether clinical use might have
unexpected implications within and beyond interactions
between doctors and patients and their families.
Academic experts in dementia, PET neuroimaging,
bioethics, and a representative from a United States-based
caregiver advocacy group discussed issues with Lilly and
Avid Radiopharmaceuticals staff. Topics included ethical is-
sues related to the diagnosis, management, and practical life
concerns faced by patients, caregivers, and physicians/health
care professionals. After the advisory board meeting, a
subgroup of attendees collaborated to refine the concepts
discussed and to write this report. In addition to a descriptionConflicts of interest: All advisors were compensated for their attendance
and participation in the Florbetapir Bioethics Advisory Board meeting.
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examples that illustrate application of bioethical principles
for decision-making with individual patients and clinical
situations. Finally, we provide practical recommendations
for clinicians to consider when discussing the use of
amyloid-PET with patients and their families.2. Background
AD is the most common cause of gradually progressive
cognitive and functional decline in older persons and ac-
counts for 60%–80% of all dementias [7,8]. Clinical
diagnosis of AD has been primarily made by assessing
progressive decline in cognitive abilities and ruling out
other common causes for cognitive impairment [9–11].
Thus, clinical information was used to infer the presence
of AD pathology. Understandably, this inference was not
always accurate and neuropathologic examination has
remained the “gold standard.” Recently, studies have
assessed the accuracy of clinical diagnostic methods for
possible or probable AD compared with neuropathology at
autopsy. One study reported that the sensitivity of clinical
AD diagnoses ranged from 70.9% to 87.3% and specificity
ranged from 44.3% to 70.8% versus pathology, depending
on the levels of certainty for either clinical or
neuropathologic criteria [12]. Difficulty in achieving accu-
rate clinical diagnoses of ADmay arise because common de-
menting diseases, such as vascular dementia, dementia with
Lewy bodies, frontotemporal dementia and others, share
many symptoms with dementia due to AD and frequently
coexist with AD pathology [13,14]. It is not surprising in
these circumstances that postmortem studies find that the
accuracy of clinical diagnosis of cognitive disorders can
range widely depending on the population studied, the
intensity of evaluation, and the skill of the clinician
[12,14–16].
Furthermore, the National Institute on Aging (NIA)-Rea-
gan neuropathologic criteria for AD classified findings as
indicating low, intermediate, or high likelihood that the
pathology caused the dementia, explicitly recognizing thatactivities not funded by industry; received research support from Avid Ra-
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always closely correlate with clinical symptoms [17].
Clinical diagnostic criteria for AD were revised in 2011
to incorporate new advances including biomarkers and to
help physicians better define the full spectrum of AD
[11,18]. The NIA-Alzheimer’s Association Task Force
guidelines define the diagnostic phases of AD to include
an asymptomatic phase, a “mild cognitive impairment”
predementia phase, and the full expression of deficits in an
AD dementia phase. According to these guidelines, a
clinical diagnosis of possible or probable AD can be made
with or without biomarker evidence, but biomarker results
are considered to increase the level of diagnostic certainty.
For the first time, the criteria incorporated biomarker
results to define “dementia unlikely due to AD” when
biomarkers of AD pathology were negative [11,18].
The clinical diagnosis of AD is primarily based on patient
history, physical examination, cognitive assessment, labora-
tory tests, and neuroimaging to identify other possible
causes or contributors to cognitive impairment [19]. Howev-
er, there is a paradigm shift in the field of cognitive impair-
ment evaluation moving away from a symptom-only
diagnosis to a biomarker-aided diagnosis. AD biomarkers
are grouped into two major categories as follows: (1)
pathology-specific biomarkers of amyloid-beta accumula-
tion, which are abnormal tracer retention on amyloid-PET
or low cerebrospinal fluid (CSF) amyloid-b1–42 levels,
with elevated CSF tau (both total and phosphorylated tau)
and (2) nonspecific neuroimaging biomarkers of neuronal
degeneration or injury, which are decreased fluorodeoxyglu-
cose uptake on PET in a specific topographic pattern
involving temporoparietal and posterior cingulate cortex,
and hippocampal atrophy on structural magnetic resonance
imaging [20]. Each of these biomarker tests has different
strengths and weaknesses regarding their utility as adjunc-
tive diagnostic tests in clinical settings when a patient is
evaluated for suspected AD [21]. Additionally, there are
important differences with respect to insurance coverage
and reimbursement for the different biomarkers.
The 2014 International Working Group guidelines revi-
sion suggests that neurodegeneration biomarkers not be
considered specific to AD for making a diagnosis in the
manner that amyloid-PET and CSF are used [22]. We focus
on potential issues relating to the use of amyloid-PET in
clinical settings, although some of the principles apply to
the clinical use of other biomarkers.3. Current state of AD diagnosis in clinical practice
Currently, primary care physicians are often the first to
learn of a cognitive complaint and perform the initial assess-
ment of a patient’s cognitive decline. The complexity asso-
ciated with differential diagnosis of cognitive impairment
and AD, in particular, can be difficult for many primary
care physicians who are not specialists in dementia care.
Postmortem neuropathology studies indicate that even de-mentia experts often have difficulty in making an accurate
clinical diagnosis of AD [12,23].
The growing epidemic of AD is becoming more widely
appreciated. However, in medical practice, there is reluc-
tance among primary care practitioners to specify the cause
of dementia or discuss an Alzheimer’s diagnosis with pa-
tients and their families [24–26]. Reasons for this
reluctance may include a lack of effective treatment
options, the physician’s lack of confidence in diagnosing
the cause of cognitive impairment (particularly early in the
course of the disease when symptoms are mild), and
concern about upsetting the patient or family [25,27]. This
often leads to a delay in determining the specific cause and
initiating treatment, or referral to a specialist, including
proactive patient and family education and support [28].
Skepticism about the ability to accurately determine the
cause of cognitive impairment often leads to skepticism
about the value of treatment.4. Current state of amyloid-PET neuroimaging
Amyloid-b deposition is most often seen in the context of
cognitive impairment due to AD, but may also be comorbid
with other neurologic conditions (e.g., cerebrovascular dis-
ease, cerebral amyloid-b angiopathy or dementia with
Lewy bodies) that may be additive to the AD pathology or
even responsible for the patients’ cognitive impairment
[13,29]. Amyloid-b pathology can also be present in
clinically normal older individuals [30]. Evidence is
mounting to suggest amyloid-b–positive clinically normal
individuals may have subtle cognitive impairments and
may be more likely to decline than amyloid-b–negative indi-
viduals. However, not all clinically normal amyloid-b–pos-
itive individuals experience meaningful cognitive decline.
Thus far, only a small percentage have been followed to
the development of dementia, and it is not clear how to pre-
dict which individuals will decline or whether other patho-
logic changes must occur to place a subject on the path to
dementia. Long-term follow-up from clinical studies is
needed to understand the role of amyloid-b pathology in
asymptomatic persons [31–34].
Therefore, although studies suggest that amyloid-PET
accurately detects the presence of b-amyloid plaques, an
important limitation of this technique is that it does not
differentiate among the different conditions with which
this neuropathology is associated. It simply informs about
the density of b-amyloid neuritic plaques, which must be
interpreted in the context of the individual patient’s symp-
tom profile and entire evaluation for cause(s) of cognitive
impairment [5,6]. Acknowledging that AD is the most
prevalent cause for dementia in older persons, it will be a
top consideration in the differential diagnosis with a
positive amyloid-PET scan result. However, this prevalence
should not preempt a thorough and broader search for
comorbid etiologies, especially for those that might be
reversible or have a different prognosis and treatment,
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vitamin imbalances, or depression. However, a negative
amyloid-PET scan excludes amyloid-b pathology with
high confidence.
The US Food and Drug Administration has approved
three F18 amyloid-PET radiotracers for clinical use
[35–37]. Because of a high level of patient and
professional interest [38], amyloid-PET has the potential
to be widely used despite constraints related to insurance
coverage, cost, and local availability from regional radio-
pharmaceutical manufacturing networks. At the same time,
there is widespread misunderstanding among the public
and many clinicians about the risks of developing cognitive
impairment, methods used to diagnose cognitive impair-
ment, different causes of dementia, and available treatment
options. Therefore, physicians with knowledge and experi-
ence incorporating amyloid-PET results into the evaluation
and care of those with dementing disease are perhaps in
the best position to use this new technology appropriately
during these introductory years.
Currently, approved drug treatments for AD dementia can
alter the symptoms and the clinical course that patients expe-
rience, but no proven treatments halt the progression of AD
or delay or prevent the onset of AD [39]. In the absence of
any disease pathology–modifying therapies, results of
amyloid-PET can nonetheless provide critical information
regarding the presence or absence and regional patterns of
b-amyloid plaque pathology. This information may, in
turn, influence treatment choice. For example, if amyloid-
PET does not demonstrate significant b-amyloid plaque pa-
thology, such that AD can be confidently excluded as a cause
of cognitive impairment, AD-directed drug treatment could
be discontinued and treatment directed to likely non-AD
causes. Alternatively, if b-amyloid plaque pathology can
be confirmed, use of AD drug treatment is justified, and
common AD complications can be identified earlier and
managed more appropriately.5. Ethical decision points when using amyloid-PET
neuroimaging
Bioethical principles should provide guidance for clinical
use, recognizing that these considerations may need to be
refined in the future as we learn more about the disease
and its prognosis and develop more efficacious treatment
options.5.1. Value of knowing the cause of cognitive impairment
Before ordering amyloid-PET, physicians, patients, and
care partners should understand the value of knowing
amyloid-b status, whether positive or negative. Patients
and families value an accurate diagnosis and knowing they
are receiving care that includes state-of-the-art assessment
procedures. A prospective study [25] found that patients
often showed reduced levels of anxiety after diagnosis of adementing condition. In another study, patients complained
that their primary care providers often failed to accurately
evaluate dementia and dismissed early symptoms, attrib-
uting them to “just aging” [40]. Some caregivers thought
the dementia evaluation was not thorough enough or the
diagnosis was based on incomplete information [40]. Care-
givers who were provided more information about the cause
of a loved one’s impairment experienced significantly lower
levels of depression, were more likely to have realistic
expectations of their dependents’ abilities, and felt more
competent and confident as caregivers [25,26].
By documenting the absence or presence of neuropa-
thology, an amyloid-PET scan may provide valuable knowl-
edge to both patients and family members. Importantly, as
with any diagnostic test, users of this technology will need
to understand that there will always be the possibility for
false-positive, false-negative, or indeterminate results (e.g.,
due to acquisition or interpretation errors). However, a nega-
tive amyloid-PET scan is inconsistent with a neuropatho-
logic diagnosis of AD, thus reducing the likelihood that
the patient’s cognitive impairment is due to AD and suggest-
ing the need for further diagnostic efforts. Additionally, in
patients suspected of having dementia or mild cognitive
impairment due to AD, there is emerging evidence that a
negative amyloid-PET scan indicates lower probability of
clinically significant cognitive deterioration for at least the
next 36 months [30,41–43]. Alternatively, a positive
amyloid-PET scan may increase a clinician’s confidence in
diagnosing AD [44,45].
A confident and specific diagnosis also helps patients and
families cope with the inherent difficulty of life-altering de-
cisions and changes in lifestyle, as well as the uncertainty of
future needs [25,46]. In some circumstances, the patient may
not wish to know the diagnosis or cannot appreciate its
meaning [47]. However, even in this situation, family mem-
bers may want to know the cause of impairment to aid their
own understanding and planning [48]. Providing patients
and family members the opportunity to make informed
autonomous plans and decisions is consistent with the
ethical principle of respect for persons, but the limitations
of the test and the possible benefits and harms of “knowing”
must be explained clearly and in advance.
The value of knowing the cause of cognitive impairment
also extends to health professionals. One ethical dilemma for
health professionals is balancing a patient’s (and caregiver’s)
right to know the cause of cognitive impairment (and thus
the provider’s obligation to disclose a diagnosis) with a pro-
vider’s wish to withhold certain information for fear this in-
formation may harm the patient. Anticipated harms could
include anxiety, depression or ill-advised decisions based
on unwarranted assumptions. When a provider withholds in-
formation in an attempt to protect a patient’s emotional well-
being, this is known as “benevolent deception.” Benevolent
deception is more common in some societal traditions than
others. Sometimes family members even request such
deception.
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may be influenced by how comfortable, or certain, the physi-
cian is in the diagnosis. Identifying the presence or absence
of amyloid-b pathology provides additional information that
is likely to enhance their confidence in the accuracy of a
diagnosis [44,45]. The AA has established a
recommendation on disclosing an AD diagnosis to an
individual: “Except in unusual circumstances, physicians
and the care team should disclose the diagnosis to the
individual with Alzheimer’s disease because of the
individual’s moral and legal right to know.” However,
patients and families who express a direct desire “not to
know” would likely not be good candidates for amyloid-
PET, although the implications of uncertainty on patient
care and future planning should be discussed.
Health care providers have an ethical responsibility to
provide support for patients and their care partners [49].
Amyloid-PET results are likely to affect how the diagnosis
and treatment recommendations are communicated and car-
ried out [44]. Low levels of physician confidence can be un-
intentionally conveyed to family members and affect their
willingness to act on recommendations. Confidence in the
accuracy of diagnosis and the value of treatments are
strongly linked to patient adherence [50]. Although a posi-
tive amyloid-PET result may indeed improve the diagnostic
confidence for an AD diagnosis, and thus help with the
ethical tension of whether or when to communicate a diag-
nosis of AD, the context of communicating a positive scan
result by the treating physician needs to be individualized
for a given patient and care partner [19].A successful business executive, age 70 began to notice progressive language
problems over the past 3 years. He is in good general health and currently on
cholesterol lowering medication. He has a family history of Alzheimer’s disease
and is concerned about his progressing language problems. He has heard about
amyloid-beta PET neuroimaging and requests the test at his next visit to his
primary care physician. The physician has not noticed any language issues and
has not performed a diagnostic workup for cognitive issues. What is the most
appropriate response for his physician to make for his request?
A. Order the scan if he can pay for it observing the principle of autonomy.
B. Observing the principle of justice, don’t order a scan unless it is covered by
insurance so socioeconomic status of the patient is not the deciding factor.
C. Defer ordering the scan until other testing has been completed and indicates
that he is an appropriate subject for the scan, observing the principle of
beneficence.
Fig. 1. A hypothetical case regarding ethical decisions physicians may
face when selecting appropriate patients for amyloid-PET. The authors
recommend approach option C. Abbreviation: PET, positron emission
tomography.5.2. Patient selection for amyloid-PET scan
Proper patient selection is fundamental before con-
ducting any diagnostic test from ethical, legal, financial,
and clinical perspectives. Recently, the AA and the SNMMI
convened the Amyloid Imaging Task Force to provide guid-
ance on appropriate patient selection to dementia care prac-
titioners, patients, and caregivers [5,6]. Appropriate use
criteria (AUC) were proposed to define the patients and
clinical circumstances in which amyloid-PET could be
used but also described situations where the use of
amyloid-PET would be considered inappropriate at this
time [5,6]. According to the AUC, amyloid-PET is appropri-
ately used by dementia experts “when there is evidence of a
cognitive complaint with objectively confirmed impairment;
when AD is a possible diagnosis, but that diagnosis is uncer-
tain after a comprehensive evaluation by an expert; and when
knowledge of amyloid-b pathology is likely to increase diag-
nostic certainty and alter patient management” [5,6].
The AUC working group recommended that amyloid-
PET is inappropriate when used for patients meeting core
clinical criteria for probable AD with typical age of onset
(indicating entirely typical symptoms and examination and
thus little reason for uncertainty); to determine dementia
severity, based solely on family history of dementia or pres-ence of the ε4 allele of apolipoprotein E (APOE); for patients
with a cognitive complaint that is unconfirmed on clinical
examination; in lieu of genotyping for suspected autosomal
carriers; in asymptomatic individuals; and for nonmedical
use (e.g., legal, insurance coverage or employment
screening) [5,6].
The potential for overuse and misuse of amyloid-PET is
an ethical concern. The desire by both physicians and pa-
tients for a definitive test that explains the cause of symp-
toms is strong. Yet, if unnecessary testing is done, it could
divert health care spending from providing interventions
that are more useful for a particular patient. From the clinical
perspective, over-reliance on amyloid-PET scan findings
during clinical care is of particular concern. Clinicians
who are not dementia specialists may be tempted to seek
simple definitive tests and might prefer obtaining an
amyloid-PET scan to completing a comprehensive clinical
evaluation or even making a referral to a dementia specialist,
especially given the pressure to see more patients in less time
[51]. Evaluation of cognitive problems requires a substantial
time commitment and complex decision making. A broad
array of conditions must be considered, and identifying a de-
menting disease can uncover medical and social issues that
are not easily addressed (e.g., social stigma resulting from
a diagnosis). Therefore, it would be inappropriate for
amyloid-PET to be performed outside of the context of a
full clinical evaluation.
Further pressures might come from patients and families
themselves, demanding that amyloid-PET be performed,
possibly when it is not medically indicated or when symp-
toms are not present. For example, first-degree relatives of
patients diagnosed with AD may request to be tested with
amyloid-PET [52]. Fig. 1 depicts a hypothetical case in
which a physician must decide the appropriate steps to
take when faced with a patient who has had a history of
progressive language problems and requests a scan. In this
A 58-year old female developed progressive memory problems over the past 2
years but she can no longer cook. Her daughter, who lives in a nearby town and
visits often, has noticed her mother becoming increasingly confused. Her
primary care provider referred her to a dementia specialist for a complete
examination, who then ordered amyloid-beta PET neuroimaging as an adjunct to
other testing. She currently lives alone and is independent in her personal care,
but she can no longer cook. What is the most appropriate method for her
physician to disclose the imaging results to her?
A. Recommend that the patient brings a friend or family member and meets with
you in person.
B. Have a staff member call the patient’s family with the results and a 
prescription based upon the scan result.
C. Because of HIPAA guidelines, tell only the patient the scan results, unless 
there is a signed release.
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appropriate subject for amyloid-PET. As recommended by
the AUC, before a decision regarding amyloid-PET, a stan-
dard work-up for causes of this patient’s symptoms should
be completed to establish the potential for AD in the differ-
ential diagnosis and to exclude other causes of the patient’s
language complaint. This may include more detailed lan-
guage and cognitive testing to confirm the presence and
type of language deficit, as well as recommended laboratory
and imaging tests if indicated. It is recommended to defer
ordering amyloid-PET pending the completion of other
testing and only if knowledge of amyloid-b pathology will
likely increase diagnostic certainty, observing the principle
of beneficence.
There are also potential issues to consider regarding the
underuse or omission of amyloid-PET. Some patients
with cognitive impairment may be misdiagnosed and,
either because of misplaced confidence in clinical methods
or failure to consider all potential causes, may not be
judged candidates for amyloid-PET [53]. In such situations,
the potential benefit of correcting diagnostic errors with
amyloid-PET would fail to be realized. Additionally,
some patients with high cognitive reserve may tolerate
significantly greater amyloid-b burden with fewer symp-
toms than those with low cognitive reserve, but when
they develop dementia, they decline more rapidly [54]. In
some instances, these patients may be regarded as “worried
well” at an initial evaluation and not be considered for
amyloid-PET. Then they and their families would lose the
advantages associated with obtaining an early and accurate
explanation for their complaint. Whether to consider the
use of amyloid-PET in situations such as these will have
to be made on a case-by-case basis considering the full
context of the clinical circumstances.
In clinical practice, patient demands may be difficult to
resist. Nevertheless, ethical principles indicate that relief
of an asymptomatic individual’s curiosity or anxiety is not
sufficient to justify obtaining a scan, both because of the
ethical principle of distributive justice (i.e., misuse of social
resources) and because the clinical implications of an
amyloid-PET result for an asymptomatic patient are not
yet known (i.e., the precautionary principle) and may lead
to drawing false conclusions. The ethical principle of benef-
icence requires that physicians not undertake interventions,
if the risks outweigh their benefits. With further research,
this risk-benefit ratio could change, particularly if current
clinical trials involving individuals with preclinical AD are
successful. At this time, there is insufficient research evi-
dence that asymptomatic persons should be scanned, except
in a research study.D. Before providing results, send the patient to a social worker or psychiatrist to 
make sure the patient will not become depressed or suicidal when told about a 
positive scan.
Fig. 2. A hypothetical case regarding ethical decisions physicians may face
when disclosing amyloid-PET results. The authors recommend approach
option A. Abbreviations: PET, positron emission tomography; HIPPA,
Health Insurance Portability and Accountability Act of 1996.5.3. Consequences of amyloid-PET results
Another concern is how, or will, the results of amyloid-
PET change the approach to the care and education of the
patient? If patients and families engage in reductionistthinking regarding amyloid results, they may attach greater
importance to a brain PET scan result than is warranted.
On the other hand, a scan could provide sufficient evidence
to motivate patients and family members to accept the diag-
nosis from the physician and to make environmental changes
if needed.
How should physicians explain what a positive or nega-
tive scan might mean to patients, especially given the limited
longitudinal and prospective amyloid-PET data that are
currently available? Simply telling patients and families
about the results of the scan without providing further expla-
nation or support could unnecessarily cause distress or
misunderstanding. This is particularly important for patients
with neuropsychological deficits in memory and language,
which may make it difficult for some individuals to under-
stand, recall, or discuss the information with their family
or friends. Fig. 2 depicts a hypothetical case in which a
physician must decide the best approach to report
amyloid-PET results for an individual patient. It is the
recommendation of the authors that in this situation a family
member should be included when disclosing the scan results.
Furthermore, recent qualitative research using mock
amyloid-PET scan results found that despite a variety of
emotional responses, care partners easily understood the
scan result and its prognostic implications and most cogni-
tively impaired patients had at least limited understanding.
All wanted quick access to further management by their phy-
sicians [47].
When test results are disclosed, practitioners should
draw on best practices in health education and risk commu-
nication to clearly convey information and provide appro-
priate resources to assist coping and promote continued
care [55]. Often referral to AA local offices can provide
additional information and support in addition to an existing
national 24/7 helpline. Results from a recent cross-sectional
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to AD underscore the importance of truly comprehending
the diagnosis from a patient perspective. This understanding
may facilitate the patient’s ability to deal with issues of
loss and to make positive life changes via available coping
strategies [56].
There has been considerable research on patient and fam-
ily reactions to genotyping of APOE, where the ε4 allele is a
known genetic risk factor for AD. The Risk Evaluation and
Education for Alzheimer’s Disease (REVEAL) study of the
psychological and behavioral impact of APOE testing of
asymptomatic first-degree relatives of AD patients may pro-
vide a model [57], although there are also important differ-
ences between these tests [58]. In a symptomatic patient,
risk for AD onset is not a concern. Instead, by providing
tangible, visual evidence about pathologic status, a positive
or negative amyloid-PET scan is difficult to refute. Inability
to deny the presence of significant pathology and sustain
alternative explanations such as “just normal aging” in the
face of such evidence could be devastating to some patients
and family members and justifies supportive care in deliv-
ering results. In this regard, amyloid-PET has more in com-
mon with diagnostic genetic testing for Huntington’s disease
or spinocerebellar atrophy.Table 1
Recommended pretest/posttest model for patient education and disclosure
of results
Prescan Postscan
 Discuss clinical value
and limitations of test
 Assess patient motiva-
tion for test and ability
to accept result
 Discuss potential ethical
and social issues
B Implications for
driving
B Future employability
B Future insurability
(long-term care, life
insurance)
 Disclose results in per-
son with trusted other
person present
 Consider problem of
automatic release of re-
sults (e.g., electronic
medical records)
 Provide advice for fam-
ily or care partner sup-
port
 Discuss prognosis and
plan for continuing care
 Develop treatment plan,
incorporating commu-
nity resources5.4. Considerations for society
The earlier the cause of dementia is determined, the more
options will be available to the patient for making life
choices. However, the results of amyloid-PET scans could
also have adverse social consequences. How will society
handle the disclosure of amyloid-b neuroimaging results?
Will a positive amyloid-PET scan result be considered a pre-
existing condition such that medical insurance benefits are
subsequently denied? How will scan results affect a patient’s
ability to obtain long-term care or disability insurance, main-
tain employability, maintain driving privileges, or retain
legal competency? These questions illustrate the potential
risk that early diagnosis can pose to patients if societal safe-
guards are not put in place. Appropriate rules or laws need to
be created protecting patients and families who receive
amyloid-PET scans from discrimination or abuse. Measures
enacted to provide legal protections for patients obtaining
genetic testing are a useful model that could be applied for
this purpose.
The use of limited health care resources must also be
considered. As new technology is often expensive, access
could be limited in a cost-constrained environment, at a
time when scan results could be particularly beneficial.
Conversely, inappropriate expenditures on scanning could
reduce the resources available for other health care needs,
including important patient and family education and sup-
port that are often given a low priority in our health care sys-
tem. Could differences in medical insurance coverage and
reimbursement by payers create regional or financially based
disparities in which only those who can afford to pay for thescan out of their pocket, or those fortunate enough to have
more comprehensive coverage, are able to benefit from the
scan?
These issues are not unique to amyloid-PET imaging
but are related to the whole process and consequence of
diagnosing a dementing disease. Solutions to these issues
will require an evolution in thinking and action by the
government, payers, and health care providers.6. Recommendations from the bioethics advisory board
As a novel technology, amyloid-PET will evoke new
practical and bioethical challenges as its clinical use
expands. Societal and personal expectations will be slow
to adjust to our better understanding of AD, necessitating
education and leadership from the medical community. We
propose the following recommendations:
1. Physician education: Physicians caring for patients
with cognitive complaints need to become familiar
with the SNMMI/AA AUC to ensure that amyloid-
PET scans are used appropriately [5,6]. Without
proper education on how to interpret test results and
counsel patients and family members, physicians
would see patient expectations and hopes
mismatched with the information that the scan can
provide. Amyloid-PET may help physicians provide
more specific and consistent advice to patients if re-
sults allow more accurate and confident diagnosis of
the cognitive impairment. However, in some situations
communicating the uncertainties regarding the mean-
ing of amyloid-PET may present new challenges,
particularly in early stage disease.
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provide education and support for patients and their
families as part of their duty to care. Table 1 presents
a proposed pretest/posttest model for patient educa-
tion and results disclosure. Patients, families, and
caregivers need to be counseled before receiving
amyloid-PET about the implications of a positive or
negative result, as well as possible impact on psycho-
social issues, including implications for family mem-
bers. Discussion should include possible actions (e.g.,
obtaining long-term care insurance) to be taken before
undergoing an extensive diagnostic workup. At the
postscan disclosure visit, physicians should ensure pa-
tients and caregivers have a good understanding of the
test results, the implications on receiving a diagnosis
for their condition, and their future treatment options.
3. Comprehensive clinical evaluation: Amyloid-PET
should be considered only as an adjunctive diagnostic
test within a comprehensive clinical evaluation of pa-
tients presenting with objectively documented cogni-
tive decline, consistent with the AUC. This should
include a full medical history; interview with a knowl-
edgeable informant; review of possible medication
adverse effects; medical, psychiatric, and neurologic
examination; assessment of cognition and function;
laboratory assessments; and structural brain imaging
where indicated.
4. Dementia specialist training and experience: Demen-
tia specialist physicians who order amyloid-PET and
integrate imaging results with other relevant clinical
evidence should have appropriate training and experi-
ence in evaluating cognitive complaints. Compassion
and support are needed while performing a dignified
and respectful diagnosis and including the patient in
discussions and management decisions.
5. Imaging specialist training and experience: Imaging
specialist physicians who oversee the technical perfor-
mance and interpretation of amyloid-PET should have
appropriate training and experience to ensure the ac-
curate image acquisition, data processing, and scan
interpretation to minimize the potential for errors.7. Conclusion
The availability of amyloid-PET for appropriate clinical
use represents a major advance in the evaluation of patients
with cognitive impairment when AD is a possible cause. We
recommend amyloid-PET be used by experienced imaging
and treating physicians in appropriately selected patients
and only in the context of a comprehensive clinical evalua-
tion with adequate explanations before and after the scan.
As with any new technology, additional efforts are needed
to continue to define the diagnostic performance, clinical
value, cost effectiveness, and ethical implications of the
procedure in clinical practice. Toward this end, a recentcase-control study has provided initial evidence that
amyloid-PET results led to revision of clinical diagnoses
and prevented the initiation of incorrect or suboptimal
treatment for patients in an urban hospital setting [59]. Addi-
tional studies are needed to determine the impact amyloid-
PET results may have on patients and family members.
From such data, we will be better able to understand and
minimize potential harms to patients, while optimizing the
potential benefits of amyloid-PET.
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1. Systematic review: Eli Lilly and Company sponsored
a multidisciplinary Bioethics Advisory Board to
discuss practical and bioethical issues that might
arise from the widespread clinical use of amyloid-
PET neuroimaging as an adjunctive diagnostic tool
to clinically evaluate patients with cognitive impair-
ment. These practical and bioethical issues are re-
ported here.
2. Interpretation: Our findings were not meant to add to
evidence-based guidelines for clinical use of amy-
loid-PET which are already being developed by the
joint efforts of the SNMMI and AA. Instead, we dis-
cussed whether clinical use might have unexpected
implications within and beyond interactions between
doctors and patients, as well as their families.
3. Future directions: The practical and bioethical prin-
ciples proposed in this manuscript provide guidance
for clinical use, recognizing that these considerations
may need to be refined in the future as we learn more
about the disease and its prognosis and develop more
efficacious treatment options.References
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